Early, effective glycemic control is key to long-term success in managing type 2 diabetes. Sitagliptin (Xiglip®) offers a trusted option for patients needing DPP-4 inhibitor monotherapy when metformin is contraindicated or not tolerated. For patients presenting with higher HbA1c levels, Sitagliptin + Metformin (Xiglip® M) provides an evidence-based fixed-dose combination that aligns with ADA/EASD consensus recommendations for early dual therapy initiation.